|
|
News Breaks | | | | March 4, 2013 | | 06:38 EDT |  | ACHN | Achillion shares should be bought ahead of data, says Piper Jaffray
Piper Jaffray recommends buying Achillion's stock ahead of data from its ACH-3102 + ribavarin for HCV in April. The firm was encouraged by interim data on ACH-3102 and continues to see the company as a likely takeout candidate. It maintains an Overweight rating on the shares. | |
|
News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT |  | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | |
|
|
|
|
|
|
